coronary vasospasm/edema

FIELD OF THE INVENTION This invention relates to novel tricyclic vasopressin receptor antagonists. By interrupting the binding of the peptide hormone vasopressin to its receptors, the antagonists are useful for treating conditions involving increased vascular resistance and cardiac

This invention relates to novel tricyclic vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions involving increased vascular resistance and

FIELD OF THE INVENTION This invention relates to novel tricyclic vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions involving increased

FIELD OF THE INVENTION This invention is directed to certain novel [1,4]benzodiazepine compounds, their synthesis, and their use as vasopressin V2 receptor antagonists. More particularly, the compounds of the present invention interfere with the binding of the peptide hormone, vasopressin, to its

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted spirobenzazepines useful as, for example, vasopressin receptor antagonists. BACKGROUND OF THE INVENTION Vasopressin is a nonpeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone effects

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted spiroheterobenzazepines useful as, for example, vasopressin receptor antagonists. BACKGROUND OF THE INVENTION Vasopressin is a nonapeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted spiroheterobenzazepines useful as, for example, vasopressin receptor antagonists. BACKGROUND OF THE INVENTION Vasopressin is a nonapeptide hormone that is secreted primarily from the posterior pituitary gland. The hormone

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions

FIELD OF THE INVENTION This invention relates to novel nonpeptide substituted vasopressin receptor antagonists. More particularly, the compounds of the present invention interrupt the binding of the peptide hormone vasopressin to its receptors and are therefore useful for treating conditions

FIELD OF THE INVENTION This invention relates to novel substituted benzimidazol-2-ones. More particularly, the compounds of the present invention modulate the binding of the peptide hormone vasopressin and neuropeptide Y to their respective receptors and are therefore useful for treating conditions